Recludix Pharma

About Recludix Pharma

Recludix Pharma is dedicated to unlocking new therapeutic possibilities to improve the lives of patients with inflammatory diseases through innovative science and biologically-validated targets.

Products & Services

STAT6 Program:A program focused on therapeutic solutions targeting STAT6 for inflammatory diseases.

Platform & Science:Focuses on SH2 domains to regulate protein activity and mediate cellular responses related to inflammatory diseases.

Specialties

Inflammatory Disease Treatments SH2 Domain Research Biologically-Validated Targets

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 123000000 MR: - FA: $123 million FAN: 123000000	D: 2026-01-12 FD: 2026-01-12	5 investors

Equity Latest

2026-01-12

$123.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nancy Whiting

President and Chief Executive Officer

A

Ajay Nirula

Executive Vice President and Head of Research and Development

M

Matthew Caldemeyer

Chief Business Officer

B

Brian Hodous

Chief Scientific Officer

C

Catherine Bovenizer

Senior Vice President of Finance and Business Operations

V

Vivek Kadambi

Experienced Pharmaceutical Executive

View 23 more team members with Pro

Unlock Full Team Directory

Recent News

Recludix Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised